Breaking News
1. India delivers its first shipment of emergency relief supplies to flood-affected Nepal      2. Turkey to evacuate citizens from Lebanon on Wednesday      3. Himachal Pradesh minister raises concerns over drone activity near sensitive border area      4. Three children died in Vijayanagar district.      5. Amethi horror: Murder accused Chandan Verma injured in police encounter during escape attempt      6. Haryana assembly elections: PM Modi urges voters to set a new record as polling begins for 90 seats      7. Foreign Minister of Argentina Diana Mondino arrived on an official visit to India      8. Union Minsiter Dharmendra Pradhan pays tribute to the youngest freedom fighter Baji Rout      9. Bodies of three more Naxalites found after encounter in Chhattisgarh's Bastar region; death toll rises to 31      10. NCP-Ajit Pawar faction leader Sachin Kurmi killed in Mumbai's Byculla      11. Two terrorists killed during encounter with security forces in J-K's Kupwara, operation underway      12. NIA conducts raids across five states in terror conspiracy case      13. Helicopter crashes in Maharashtra's Pune district; two persons feared killed, say police      14. 7 more children take ill after having mid-day meal at Thane school; 45 hospitalised so far      15. PM inaugurated and laid foundation stones for 109 projects under AMRIT      16. Andhra govt notifies new liquor policy, expects to gain Rs 5,500 cr revenue      17. 'My Family Being Targeted': Siddaramaiah Reacts To Row Over Wife's Move To Return MUDA Plots      18. Israel begins 'targeted ground raids' on Hezbollah in Lebanon amid ceasefire calls      19. Jammu and Kashmir Assembly Elections 2024 Live Updates: 65.65% voter turnout in Phase 3 polling for final 40 seats,      20. Iran Preparing To 'Imminently' Launch Missile Attack On Israel: US Official     

Glenmark Pharmaceuticals Gains USFDA Approval for Apremilast Tablets, Targets Skin Care Sector

  • Posted on October 17, 2023
  • Business
  • By Arijit Dutta
  • 283 Views

Glenmark Pharmaceuticals, a prominent player in the pharmaceutical industry, achieved a significant milestone as it received final approval from the US Food & Drug Administration (USFDA) for its Apremilast Tablets. These tablets are intended for the treatment of plaque psoriasis and oral ulcers, further enhancing Glenmark's presence in the dermatology sector.

Glenmark Pharmaceuticals Gains USFDA Approval for Apremilast Tablets, Targets Skin Care Sector Image Source -www.health.economictimes.indiatimes.com

Glenmark Pharmaceuticals, a prominent player in the pharmaceutical industry, achieved a significant milestone as it received final approval from the US Food & Drug Administration (USFDA) for its Apremilast Tablets. These tablets are intended for the treatment of plaque psoriasis and oral ulcers, further enhancing Glenmark's presence in the dermatology sector.

The US FDA's approval covers Apremilast Tablets in three distinct strengths: 10 mg, 20 mg, and 30 mg. These tablets are a generic alternative to Amgen Inc.'s Otezla tablets, which come with the same strengths. Glenmark's announcement highlighted the potential of Apremilast Tablets, underlining their role in treating a range of skin conditions.

Otezla tablets, which serve a similar purpose, achieved staggering annual sales of approximately USD 3.7 billion in the 12 months leading up to August 2023, as reported by IQVIA sales data. This approval positions Glenmark Pharmaceuticals to tap into this lucrative market and cater to the needs of patients with psoriasis arthritis and moderate to severe plaque psoriasis, a specific skin ailment.

Glenmark Pharma, with an impressive portfolio of 188 products authorized for distribution in the US market, currently has 50 Abbreviated New Drug Applications (ANDAs) pending approval with the US FDA. This showcases the company's commitment to expanding its presence in the pharmaceutical industry.

In addition to its dermatology offerings, Glenmark Pharmaceuticals maintains a robust presence across various segments, including branded, generic, and over-the-counter (OTC) products. It primarily focuses on respiratory, dermatology, and oncology products.

Also Read: Oil Prices Fall Over $1 As Hopes For Venezuela Deal Rise And Middle East Crisis Stays Local

Operating across four continents with ten manufacturing facilities and a presence in over 80 countries, Glenmark is well-positioned to cater to a global clientele. Moreover, in a strategic move, the pharma giant's subsidiary, Glenmark Specialty SA, recently entered into a distribution and license agreement with Cosmo Pharmaceuticals NV. The partnership aims to introduce Winlevi (Clascoterone cream 1%) in the European and South African markets. Glenmark will have exclusive rights to commercialize Winlevi in 15 EU countries, South Africa, and the UK, offering a promising solution for acne treatment in patients aged 12 years and older.

Glenmark's success is reflected in the stock market, with Glenmark shares trading 0.63 percent higher at Rs 802.50 on the Bombay Stock Exchange (BSE) at 9.43 AM. This marks the third consecutive day of positive performance for the company's shares.

Author
No Image
Author
Arijit Dutta

You May Also Like